Navigation Links
Drug used to treat hypertension effective in countering Migraines

Migraines,headaches which involve intense throbbing pain, sometimes accompanied by visual disturbances as well as sensitivity to light and sounds, have been found to respond to a drug hitherto used to treat high blood pressure//.

Norwegian researchers reported that drugs like candesartan cilexetil (Atacand) reduces the number and severity of migraine attacks. The Norwegian team decided to study Atacand after a colleague in their department noticed his migraines disappeared when he started taking the drug lisinopril for his high blood pressure. The researchers reasoned that if the anti-migraine effect was linked to the lisinopril, which reduces the amount of angiotensin II, a drug such as Atacand, which works by blocking angiotensin II and called an angiotensin II receptor blocker, might be even more effective. Angiotensin II is a substance that constricts blood vessels and can make blood pressure rise.

The study involved 65 patients of ages 20 to 65, who experienced 2 to 6 attacks in a month. The researchers assigned 30 patients to take the placebo in the first 12 week period and a 16mg Atacand in the following 12 week period. The other group of 30 underwent the reverse of the above regime (ie. Atacand in the first 12 weeks and placebo in the next 12 weeks), though none of the groups were aware whether they were taking the placebo or the medicine.

Researchers found that during the 12 week periods, the average number of days with headaches was 18.5 with placebo and 13.6 with the medicine. 30 to 45 per cent of the subjects showed 50 per cent reduction in one of the outcome measures, like headache severity. The drug also a showed a reduction in the length of attacks, in addition to the reduction in the number of headache and migraine days.

The study, though very interesting and beneficial to the millions of migraine sufferers around the globe, has not been able to find out how these drugs work to reduce or prevent migraines . An expert neurologist says that the drug might presumably have multiple effects on multiple sites in the brain. The researchers also said that they do not have any predictors as yet, to who might respond to this type of medication and that they are trying to investigate this aspect, both with respect to blood pressure variations and to genetic variations.

The drug Atacand is manufactured by AstraZeneca, which provided the necessary medication and financial support for the study.
'"/>




Related medicine news :

1. Thyroid hormone treatment hastens recovery after cardiac surgery
2. Feeding channel created by malaria parasite - a new target for malaria treatments
3. New drug to treat Heart Attack and damaged tissue
4. Now umbilical cord helps in stroke treatment.
5. Now AIDS treatment comes dirt-cheap
6. Breast cancer treatment to be determined by gene test
7. Hemopurifier may revolutionise AIDS treatment
8. New drug helps boost cancer treatment
9. Antidepressants come in handy for patients on treatment for hepatitis, cancers and multiple sclerosis
10. Experimental treatment for Ebola Virus Shows promising results in mice
11. Radioactive Seeds used in Prostate Cancer treatment can migrate with the body
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/26/2017)... ... 2017 , ... The National Business Research Institute (NBRI) is ... Emergency Medical Technicians and welcomes this organization to the NBRI Circle of ... Ph.D. , CEO & Organizational Psychologist at NBRI. “This award is a result ...
(Date:4/26/2017)... ... April 26, 2017 , ... RawTrition now brings you BioEnergy which ... nutrients from SUPERFOODS! , RawTrition is taking nutrients to the next level! ... the body recognizes its raw form (unlike the synthetically made options that are on ...
(Date:4/26/2017)... Pa. (PRWEB) , ... April ... ... division, which provides an agile ecosystem and domain expertise for sponsors and ... configurable randomization and trial supply management (RTSM) software platform. Bioclinica AGILE ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... collaboration, announces Mirroring360 Pro . This new addition to the Mirroring360 product ... for education and business. , Mirroring360 Pro enables educators, business professionals and individuals ...
(Date:4/25/2017)... ... 25, 2017 , ... A stressful work environment can hurt the physical and ... and performance in the workplace. The goal of Clearview Resolution Services has always been ... April, Clearview Resolution Services will be shutting down the office early on Fridays. The ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017 The Mobile X-Ray product ... a healthy CAGR during the forecast period Mobile ... the global digital mobile X-Ray devices market, which is estimated ... 2017, expanding at a CAGR of 7% over the forecast ... opportunity of more than US$ 100 Mn in 2017 over ...
(Date:4/19/2017)... DALLAS , April 19, 2017  Vanderbilt University ... first patients in Nashville , Tennesse ... Lower Esophageal Sphincter Stimulation for GERD (LESS GERD) trial. ... to provide long-term reflux control by restoring normal function ... nearly 65 million people in the United ...
(Date:4/19/2017)... , April 19, 2017  New research provides evidence ... advanced Parkinson,s, according to a study released today that will ... Annual Meeting in Boston , April ... to the treatment of Parkinson,s disease, the oral drug levodopa ... life and longevity. But as the disease progresses, the effects ...
Breaking Medicine Technology: